As part of the reshuffle, I-Mab will prioritise the advancement of givastomig, a CLDN18.2 x 4-1BB bispecific antibody, ...

The firm is shifting its resources to fund and expand its Phase I clinical trial of givastomig in CLDN18.2-expressing advanced solid tumor patients.

With new treatments in neurology, and more in development in cardiology and autoimmune diseases, precision medicine is moving beyond cancer and rare disease.

Russia and other hostile states have become increasingly brazen in adopting “gray zone” attacks against Europe and the United States, leaving defense officials with a dilemma: How to respond ...